Sabinsa showcases its metabolite certification for curcumin, as nutraceutical efficacy and bioavailability impress

03 Feb 2023 --- As the nutraceutical industry continues to tout the cognitive, healthy aging, weight management properties and various other benefits of curcumin, Sabinsa highlights Curcumin C3 Reduct, the company’s curcumin metabolite, which was recently granted Novel Food status by the European Food Safety Authority (EFSA).

“Curcumin 3 Reduct is the only EFSA-approved curcumin metabolite in the market,” Dr. Umar Jan, Sabinsa’s president of European Operations, tells NutritionInsight. “We got the approval in 2022, and nobody else has this approval to date.”

“Apart from that, there are also a number of patents which are pending and products which we’ll be introducing in 2023.”

Curcumin is often touted for its healthy aging properties, due to the numerous proven benefits in joint health, cognition, memory and improved bioavailability.Proven Benefits
Curcumin C3 Reduct consists of more than 95% tetrahydrocurcuminoids and is safe at 140 mg per day, according to the EFSA.

Curcumin has been shown to have several potential health benefits, including neuroprotective properties, improvement of cognition and memory, increased joint health and weight management properties, to name a few.

“We are positioning this product for different areas like healthy aging, internal organ health and also for the sports industry where it activates AMP kinase (an activated protein that improves cellular metabolism),” Dr. Jan explains.

Improved bioavailability
According to Dr. Jan, Curcumin C3 Reduct is also unique because it is a metabolite of curcumin, which he says significantly increases its bioavailability. Additionally, it is the first curcumin metabolite on the market and it is also colorless, which makes it easy to formulate, especially in sports nutrition sector.

“There are so many products of curcumin which talk about bioavailability, which are using artificial ingredients or different agents to increase the bioavailability,” Dr. Jan explains. “This product contains pharmacological active metabolites of curcuminoids, and it is well  established that ultimately real health benefits of curcuminoids is attributed to active metabolites – this is in the form of Curcumin C3 Reduct.”

“It has the ability to provide health benefits immediately inside cells therefore makes it unique and versatile in this particular market.”

Future Innovations
Dr. Jan also outlines Sabinsa’s path for future innovations, noting that science is the backbone of the company’s innovations. Dr. Umar Jan, President of European Operations at Sabinsa.

“For 2023, the major products which we will focus on – of which, of course, Curcumin C3 Reduct is one – we also have Shagandha, our correctly standardized ashwagandha and we have Nigellin from Nigella sativa.”

“We also have products for weight management,” says Dr. Jan. “Cirpusins, which is standardized for 6% of stilbenes.”

The product comes from Cyperus rotundus, also known as nut grass. The stilbenes of which have been shown to help reduce body weight and visceral fat.

“We have clinical studies done on this product that show its efficacy as an innovative weight management product,” Dr. Jan concludes. “Then we have, of course, microbiome-related products, such as the non-resistant starch from curcumin in Starmeric, which is a product on which we will also be focusing.”

By William Bradford Nichols

To contact our editorial team please email us at editorial@cnsmedia.com